Keen to help Endomag extend global reach
Endomag, the Cambridge-based cancer healthcare company, has appointed experienced life sciences specialist Peter Keen as non-executive director.
Since the launch of Magseed®, Endomag’s breast lesion localisation device, last November, interest has exceeded expectations. More than 150 hospitals, including 30 of the top 50 ranked cancer centres in the US, are now due to evaluate the technology in the first half of 2017. To build on this success, Keen will focus on supporting the company as it further extends its international reach.
Keen has over 30 years’ experience in the management and financing of life science businesses. He founded the technology investment firm Cambridge Innovation Capital and has served on the board of many private and public companies.
He is currently a director of both MRC Technology Limited and the Biotechnology Growth Trust plc, a £280 million investment trust investing in global biotechnology.
For nine years he was the senior independent director of Abcam plc and was a co-founder of Chiroscience Group plc, where he led the £102m initial public offering.
Keen was co-founder of the venture capital firm Merlin Biosciences and, as UK managing director, was responsible for many early stage healthcare investments.